Peregrine Asset Advisers, Inc. Novo Cure LTD Transaction History

Peregrine Asset Advisers, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 05, 2022	SELL	$60.15 - $84.52 $665,980 - $935,805	-11,072 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$75.08 - $121.99 $4,129 - $6,709	-55 Reduced 0.49%	11,072 $831,000
Q3 2021 Nov 09, 2021	BUY	$116.17 - $194.55 $182,154 - $305,054	1,568 Added 16.4%	11,127 $1.29 Million
Q2 2021 Aug 12, 2021	BUY	$130.4 - $225.58 $1.25 Million - $2.16 Million	9,559 New	9,559 $2.12 Million
Q1 2021 May 13, 2021	SELL	$124.11 - $190.17 $144,215 - $220,977	-1,162 Closed	0 $0
Q4 2020 Feb 04, 2021	BUY	$112.16 - $174.14 $130,329 - $202,350	1,162 New	1,162 $201,000

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.25B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Peregrine Asset Advisers, Inc., based on Form 13F filings with the SEC.

Stay updated on Peregrine Asset Advisers, Inc. with notifications on news.